Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

23.96 -0.55 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 210,390
Open 24.73
Bid (Size) 21.50 (3)
Ask (Size) 27.51 (1)
Prev. Close 24.51
Today's Range 23.86 - 24.77
52wk Range 14.59 - 35.84
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high... 
From Castle Biosciences, Inc.
Via GlobeNewswire
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
From Castle Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-14.6%
-14.6%
1 Month
+5.5%
+5.5%
3 Month
+46.7%
+46.7%
6 Month
+19.3%
+19.3%
1 Year
-26.0%
-26.0%

More News

Read More
Earnings Scheduled For August 4, 2025
Via Benzinga
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
From Castle Biosciences, Inc.
Via GlobeNewswire
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
Here are the top movers in Tuesday's session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Tuesday's session: top gainers and losers
Via Chartmill
Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
Via Chartmill
These stocks are moving in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Castle (CSTL) Q2 Revenue Tops Estimates
Via The Motley Fool
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Castle Biosciences Inc (NASDAQ:CSTL) Surges After Posting Strong Q2 2025 Earnings Beat
Via Chartmill
Topics Earnings
Castle Biosciences Reports Second Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Examining the Future: Castle Biosciences's Earnings Outlook
Via Benzinga
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
From Castle Biosciences, Inc.
Via GlobeNewswire
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?
Yes, Castle Biosciences, Inc. - Common stock is publicly traded.
What exchange does Castle Biosciences, Inc. - Common stock trade on?
Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Castle Biosciences, Inc. - Common stock?
The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market
What is the current price of Castle Biosciences, Inc. - Common stock?
The current price of Castle Biosciences, Inc. - Common stock is 23.96
When was Castle Biosciences, Inc. - Common stock last traded?
The last trade of Castle Biosciences, Inc. - Common stock was at 10/27/25 04:00 PM ET
What is the market capitalization of Castle Biosciences, Inc. - Common stock?
The market capitalization of Castle Biosciences, Inc. - Common stock is 603.01M
How many shares of Castle Biosciences, Inc. - Common stock are outstanding?
Castle Biosciences, Inc. - Common stock has 603M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.